A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
allow for the importation of affordable and safe insulin 
by wholesale distributors, pharmacies, and individuals. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Affordable Insulin Act 
4
of 2019’’. 
5
SEC. 2. IMPORTING AFFORDABLE AND SAFE INSULIN. 
6
(a) IN GENERAL.—The Federal Food, Drug, and 
7
Cosmetic Act is amended by inserting after section 804 
8
of such Act (21 U.S.C. 384) the following: 
9
03:07 Mar 14, 2019
H1478
2 
•HR 1478 IH
‘‘SEC. 804A. IMPORTATION OF SAFE AND AFFORDABLE IN-
1
SULIN BY WHOLESALE DISTRIBUTORS, PHAR-
2
MACIES, AND INDIVIDUALS. 
3
‘‘(a) IN GENERAL.— 
4
‘‘(1) REGULATION.—Not later than 180 days 
5
after the date of enactment of this section, the Sec-
6
retary shall promulgate regulations permitting the 
7
importation of qualifying insulin into the United 
8
States, in accordance with this section. 
9
‘‘(2) RELATION TO SECTION 804.—Nothing in 
10
section 804 shall be construed to supercede or limit 
11
the provisions of this section. 
12
‘‘(b) DEFINITIONS.—For purposes of this section: 
13
‘‘(1) CERTIFIED FOREIGN SELLER.—The term 
14
‘certified foreign seller’ means a licensed foreign 
15
pharmacy or foreign wholesale distributor that the 
16
Secretary certifies under subsection (d)(1)(B), that 
17
pays the fee required under subsection (d)(1)(C), 
18
and that is included on the list described in sub-
19
section (c). 
20
‘‘(2) FOREIGN
WHOLESALE
DISTRIBUTOR.— 
21
The term ‘foreign wholesale distributor’ means a 
22
person (other than a manufacturer, a manufactur-
23
er’s co-licensed partner, a third-party logistics pro-
24
vider, or a repackager) engaged in wholesale dis-
25
tribution. 
26
03:07 Mar 14, 2019
H1478
3 
•HR 1478 IH
‘‘(3) IMPORTER.—The term ‘importer’ means a 
1
dispenser (as defined in section 581(3)) or wholesale 
2
distributor registered under section 503(e) who im-
3
ports insulin into the United States in accordance 
4
with this section. 
5
‘‘(4) LICENSED
FOREIGN
PHARMACY.—The 
6
term ‘licensed foreign pharmacy’ means a pharmacy 
7
located in Canada, or subject to subsection (e), an-
8
other applicable country, that— 
9
‘‘(A) operates in accordance with applica-
10
ble pharmacy standards set forth by the provin-
11
cial pharmacy rules and regulations enacted in 
12
Canada, or, subject to subsection (e), such ap-
13
plicable rules and regulations of the permitted 
14
country in which such seller is located; and 
15
‘‘(B) is licensed to operate and dispense in-
16
sulin to individuals in Canada, or, subject to 
17
subsection (e), the permitted country in which 
18
the pharmacy is located. 
19
‘‘(5) QUALIFYING INSULIN.—The term ‘quali-
20
fying insulin’ means insulin that— 
21
‘‘(A) is approved for use in patients, and 
22
marketed, in Canada, or subject to subsection 
23
(e), approved for use in patients, and marketed, 
24
in another permitted country; 
25
03:07 Mar 14, 2019
H1478
4 
•HR 1478 IH
‘‘(B) is manufactured in a facility reg-
1
istered under subsection (b)(1) or (i) of section 
2
510 that is in compliance with good manufac-
3
turing practices regulations of the Food and 
4
Drug Administration; 
5
‘‘(C) has the same active ingredient or in-
6
gredients, route of administration, and strength 
7
as an insulin approved under chapter V, or is 
8
biosimilar to an approved biological product and 
9
has the same route of administration and 
10
strength as the approved biological product; and 
11
‘‘(D) is labeled in accordance with— 
12
‘‘(i) the laws of Canada, or another 
13
country from which importation is per-
14
mitted pursuant to subsection (e); and 
15
‘‘(ii) the requirements promulgated by 
16
the Secretary, which shall include labeling 
17
in English; 
18
‘‘(6) VALID
PRESCRIPTION.—The term ‘valid 
19
prescription’ means a prescription that is issued for 
20
a legitimate medical purpose in the usual course of 
21
professional practice by— 
22
‘‘(A) a practitioner who has conducted at 
23
least 1 in-person medical evaluation of the pa-
24
tient; or 
25
03:07 Mar 14, 2019
H1478
5 
•HR 1478 IH
‘‘(B) a covering practitioner. 
1
‘‘(c) PUBLICATION OF CERTIFIED FOREIGN SELL-
2
ERS.—The Secretary shall publish on a dedicated internet 
3
website a list of certified foreign sellers, including the 
4
internet website address, physical address, and telephone 
5
number of each such certified foreign seller. 
6
‘‘(d) ADDITIONAL CRITERIA.— 
7
‘‘(1) CERTIFIED FOREIGN SELLERS.— 
8
‘‘(A) IN GENERAL.—To be a certified for-
9
eign seller, such seller shall— 
10
‘‘(i) be certified by the Secretary in 
11
accordance with subparagraph (B); 
12
‘‘(ii) pay the registration fee estab-
13
lished under subparagraph (C); and 
14
‘‘(iii) sell only qualifying insulin to im-
15
porters or individuals who import insulin 
16
into the United States in accordance with 
17
this section. 
18
‘‘(B) CERTIFICATION.—To be a certified 
19
foreign seller, the Secretary shall certify that 
20
such seller— 
21
‘‘(i) is a foreign wholesale distributor 
22
or licensed foreign pharmacy operating an 
23
establishment, which may include an online 
24
foreign pharmacy, that is located in Can-
25
03:07 Mar 14, 2019
H1478
6 
•HR 1478 IH
ada, or, subject to subsection (e), another 
1
permitted country; 
2
‘‘(ii) is engaged in the distribution or 
3
dispensing of an insulin that is imported or 
4
offered for importation into the United 
5
States; 
6
‘‘(iii) has been in existence for a pe-
7
riod of at least 5 years preceding the date 
8
of such certification and has a purpose 
9
other than to participate in the program 
10
established under this section; 
11
‘‘(iv) in the case of a certified foreign 
12
seller that is a licensed foreign pharmacy, 
13
agrees to dispense qualifying insulin to an 
14
individual in the United States only after 
15
receiving a valid prescription, as described 
16
in paragraph (2)(C); 
17
‘‘(v) has processes established by the 
18
seller, or participates in another estab-
19
lished process, to certify that the physical 
20
premises and data reporting procedures 
21
and licenses are in compliance with all ap-
22
plicable laws and regulations of Canada, 
23
or, subject to subsection (e), the permitted 
24
country in which the seller is located, and 
25
03:07 Mar 14, 2019
H1478
7 
•HR 1478 IH
has implemented policies designed to mon-
1
itor ongoing compliance with such laws 
2
and regulations; 
3
‘‘(vi) conducts or commits to partici-
4
pate in ongoing and comprehensive quality 
5
assurance programs and implements such 
6
quality 
assurance 
measures, 
including 
7
blind testing, to ensure the veracity and re-
8
liability of the findings of the quality as-
9
surance program; 
10
‘‘(vii) agrees that, pursuant to sub-
11
section (g), laboratories approved by the 
12
Secretary may be authorized to conduct in-
13
sulin testing to determine the chemical au-
14
thenticity of sample insulin products; 
15
‘‘(viii) agrees to notify the Secretary, 
16
importers, and individuals of insulin recalls 
17
in Canada, or pursuant to subsection (e), 
18
the permitted country in which the seller is 
19
located, and agrees to cease, or refrain 
20
from, exporting such insulin; 
21
‘‘(ix) has established, or will establish 
22
or participate in, a process for resolving 
23
grievances, as defined by the Secretary, 
24
03:07 Mar 14, 2019
H1478
8 
•HR 1478 IH
and will be held accountable for violations 
1
of established guidelines and rules; 
2
‘‘(x) except as otherwise permitted 
3
under this section, does not sell products 
4
that the seller could not otherwise legally 
5
sell in Canada, or, subject to subsection 
6
(e), the permitted country in which such 
7
seller is located to customers in the United 
8
States; and 
9
‘‘(xi) meets any other criteria estab-
10
lished by the Secretary. 
11
‘‘(C) CERTIFICATION FEE.—Not later than 
12
30 days before the start of each fiscal year, the 
13
Secretary shall establish a fee to be collected 
14
from foreign sellers for such fiscal year that are 
15
certified under subparagraph (B), in an amount 
16
that is sufficient, and not more than necessary, 
17
to pay the costs of administering the program 
18
under this section, and enforcing this section 
19
pursuant to section 303(h), for that fiscal year. 
20
‘‘(D) RECERTIFICATION.—A certification 
21
under subparagraph (B) shall be in effect for a 
22
period of 2 years, or until there is a material 
23
change in the circumstances under which the 
24
foreign seller meets the requirements under 
25
03:07 Mar 14, 2019
H1478
9 
•HR 1478 IH
such subparagraph, whichever occurs earlier. A 
1
foreign seller may reapply for certification 
2
under such subparagraph (B), in accordance 
3
with a process established by the Secretary. 
4
‘‘(2) INDIVIDUALS.—An individual may import 
5
a qualifying insulin described in subsection (b) from 
6
Canada or another country pursuant to subsection 
7
(e) if such qualifying insulin— 
8
‘‘(A) is dispensed, including through an 
9
online pharmacy, by a certified foreign seller 
10
that is a licensed foreign pharmacy; 
11
‘‘(B) is purchased for personal use by the 
12
individual, not for resale; and 
13
‘‘(C) is filled only after providing to the li-
14
censed foreign pharmacy a valid prescription 
15
issued by a health care practitioner licensed to 
16
practice in a State in the United States. 
17
‘‘(e) IMPORTATION FROM OTHER COUNTRIES.—Be-
18
ginning on the date that is 2 years after the date on which 
19
final regulations are promulgated to carry out this section, 
20
if, based on a review of the evidence obtained after such 
21
effective date, including the reports submitted under sec-
22
tion 2(d) of the Affordable Insulin Act of 2019, that im-
23
portation of qualifying insulin from Canada under this 
24
section resulted in cost savings for consumers in the 
25
03:07 Mar 14, 2019
H1478
10 
•HR 1478 IH
United States and increased access to safe insulin, the 
1
Secretary shall have the authority to permit importation 
2
of qualifying insulin by importers and individuals from, 
3
in addition to Canada, any country that— 
4
‘‘(1) is a member of the Organisation for Eco-
5
nomic Co-operation and Development; and 
6
‘‘(2) has statutory or regulatory standards for 
7
the approval and sale of insulin that are comparable 
8
to the standards in the United States and that— 
9
‘‘(A) authorize the approval of drugs only 
10
if a drug has been determined to be safe and 
11
effective by experts employed by or acting on 
12
behalf of a governmental entity and qualified by 
13
scientific training and experience to evaluate 
14
the safety and effectiveness of drugs; 
15
‘‘(B) require that any determination of 
16
safety and effectiveness described in subpara-
17
graph (A) be made on the basis of adequate 
18
and well-controlled investigations, including 
19
clinical investigations, as appropriate, con-
20
ducted by experts qualified by scientific training 
21
and experience to evaluate the safety and effec-
22
tiveness of drugs; 
23
‘‘(C) require the methods used in, and the 
24
facilities and controls used for, the manufac-
25
03:07 Mar 14, 2019
H1478
11 
•HR 1478 IH
ture, processing, and packing of drugs in the 
1
country to be adequate to preserve the identity, 
2
quality, purity, and strength of the drugs; and 
3
‘‘(D) require the reporting of adverse reac-
4
tions to drugs and establish procedures to re-
5
call, and withdraw approval of, drugs found not 
6
to be safe or effective. 
7
‘‘(f) LABELING.—Any qualifying insulin imported 
8
that meets the labeling requirements described in sub-
9
section (b)(5)(A)(iv) is deemed not misbranded for pur-
10
poses of section 502. 
11
‘‘(g) INSULIN TESTING LABORATORIES.—The Sec-
12
retary may approve one or more laboratories to conduct 
13
random testing of insulin sold by certified foreign sellers 
14
to assess the chemical authenticity of such insulin. 
15
‘‘(h) UNFAIR AND DISCRIMINATORY ACTS AND PRAC-
16
TICES.—It is unlawful for a manufacturer, directly or indi-
17
rectly (including by being a party to a licensing agreement 
18
or other agreement)— 
19
‘‘(1) to discriminate by charging a higher price 
20
for an insulin sold to a certified foreign seller that 
21
sells such insulin to an importer in accordance with 
22
this section than the price that is charged, inclusive 
23
of rebates or other incentives to the country from 
24
which the insulin is exported, to another person that 
25
03:07 Mar 14, 2019
H1478
12 
•HR 1478 IH
is in the same country and that does not import 
1
such insulin into the United States in accordance 
2
with this section; 
3
‘‘(2) except with respect to an insulin on the 
4
drug shortage list under section 506E, discriminate 
5
by denying, restricting, or delaying supplies of an in-
6
sulin to a certified foreign seller, on account of such 
7
seller’s status as a certified foreign seller, that sells 
8
such insulin to an importer in accordance with this 
9
section, or by publicly, privately, or otherwise refus-
10
ing to do business with such a certified foreign seller 
11
on account of such seller’s status as a certified for-
12
eign seller; 
13
‘‘(3) cause there to be a difference (including a 
14
difference in active ingredient, route of administra-
15
tion, bioequivalence, strength, formulation, manufac-
16
turing establishment, manufacturing process, or per-
17
son that manufactures the insulin) between an insu-
18
lin for distribution in the United States and the in-
19
sulin for distribution in Canada or another per-
20
mitted country, subject to subsection (e), for the 
21
purpose of avoiding sales by certified foreign sellers; 
22
or 
23
‘‘(4) except with respect to an insulin on the 
24
drug shortage list under section 506E, engage in 
25
03:07 Mar 14, 2019
H1478
13 
•HR 1478 IH
any other action to restrict, prohibit, or delay the 
1
importation of an insulin under this section. 
2
‘‘(i) INFORMATION AND RECORDS.— 
3
‘‘(1) BIANNUAL REPORTS.—Each importer shall 
4
submit biannual reports to the Secretary which shall 
5
contain, for each qualifying insulin imported into the 
6
United States— 
7
‘‘(A) the unique facility identifier of the 
8
manufacturer of the insulin, described in sec-
9
tion 510; 
10
‘‘(B) the transaction information described 
11
in section 581(26) (other than the information 
12
described in subparagraph (C)); and 
13
‘‘(C) the price paid by the importer for the 
14
insulin. 
15
‘‘(2) MAINTENANCE
OF
RECORDS
BY
SEC-
16
RETARY.—The Secretary shall maintain information 
17
and documentation submitted under paragraph (1) 
18
for such period of time as the Secretary determines 
19
to be appropriate. 
20
‘‘(j) SUSPENSION OF IMPORTATION.— 
21
‘‘(1) PATTERNS
OF
NONCOMPLIANCE.—The 
22
Secretary shall require that importation of a specific 
23
qualifying insulin or importation by a specific cer-
24
tified foreign seller or importer pursuant to this sec-
25
03:07 Mar 14, 2019
H1478
14 
•HR 1478 IH
tion be immediately suspended if the Secretary de-
1
termines that there is a pattern of importation of 
2
such specific insulin or by such specific seller or im-
3
porter that involves counterfeit drugs, drugs that 
4
have been recalled or withdrawn, or drugs in viola-
5
tion of any requirement of this section, until an in-
6
vestigation is completed and the Secretary deter-
7
mines that importation of such drug or by such sell-
8
er or importer does not endanger the public health. 
9
‘‘(2) TEMPORARY SUSPENSION.—The Secretary 
10
may require that importation of a specific qualifying 
11
insulin or importation by a specific certified foreign 
12
seller or importer pursuant to this section be tempo-
13
rarily suspended if, with respect to such insulin, sell-
14
er, or importer, there is a violation of any require-
15
ment of this section or if the Secretary determines 
16
that importation of such insulin or by such seller or 
17
importer might endanger the public health. Such 
18
temporary suspension shall apply until the Secretary 
19
completes an investigation and determines that im-
20
portation of such insulin or by such seller or im-
21
porter does not endanger the public health. 
22
‘‘(k) SUPPLY CHAIN SECURITY.— 
23
‘‘(1) PURCHASE FROM REGISTERED FACILITIES 
24
AND CERTIFIED FOREIGN SELLERS.— 
25
03:07 Mar 14, 2019
H1478
15 
•HR 1478 IH
‘‘(A) IN GENERAL.—Except as provided in 
1
subparagraph (B), certified foreign sellers who 
2
sell qualifying insulin for importation into the 
3
United States pursuant to this section may pur-
4
chase such insulin only from manufacturers or 
5
entities registered under section 510 or other 
6
certified foreign sellers. 
7
‘‘(B) EXCEPTION.—Certified foreign sellers 
8
who sell qualifying insulin for importation into 
9
the United States pursuant to this section may 
10
purchase such insulin from foreign sellers in 
11
Canada or another permitted country, even if 
12
such foreign seller is not a manufacturer reg-
13
istered under section 510 or a certified foreign 
14
seller, if the Secretary enters into a memo-
15
randum of understanding or cooperative agree-
16
ment with Canada, or such other permitted 
17
country, to ensure compliance, to the extent ap-
18
propriate and feasible, with subchapter H of 
19
chapter V. The Secretary shall seek to enter 
20
into such a memorandum of understanding or 
21
cooperative agreement with Canada and each 
22
country from which importation is permitted 
23
under subsection (e). 
24
03:07 Mar 14, 2019
H1478
16 
•HR 1478 IH
‘‘(2) IMPORTATION TRACING.—Certified foreign 
1
sellers shall provide importers with the unique facil-
2
ity identifier associated with the manufacturer reg-
3
istered under section 510 of the qualifying insulin 
4
and the information under paragraph (25), para-
5
graph (26) (other than subparagraph (C)), and sub-
6
paragraphs (D), (F), and (G) of paragraph (27) of 
7
section 581. Certified foreign sellers shall provide 
8
such information to individuals purchasing such in-
9
sulin, upon request. 
10
‘‘(l) REMS.—In the case of an importer that imports 
11
a qualifying insulin, where the insulin has the same active 
12
ingredient or ingredients, route of administration, and 
13
strength as an insulin approved under chapter V, or is 
14
biosimilar to an approved biological product and has the 
15
same route of administration and strength as the approved 
16
biological product, and where the approved product is sub-
17
ject to elements to assure safe use under section 505–1, 
18
such importer shall be subject to such elements to assure 
19
safe use, as applicable and appropriate. 
20
‘‘(m) CONSTRUCTION.—Nothing in this section limits 
21
the authority of the Secretary relating to the importation 
22
of insulin, other than with respect to section 801(d)(1) 
23
as provided in this section.’’. 
24
03:07 Mar 14, 2019
H1478
17 
•HR 1478 IH
(b) PENALTIES WITH RESPECT TO ONLINE PHAR-
1
MACIES.—Section 303 of the Federal Food, Drug, and 
2
Cosmetic Act (21 U.S.C. 333) is amended by adding at 
3
the end the following: 
4
‘‘(h) In the case of person operating an internet 
5
website, whether in the United States or in another coun-
6
try, that violates section 301(aa) by— 
7
‘‘(1) selling, by means of the internet, with the 
8
intent to defraud or mislead or with reckless dis-
9
regard for safety of the public, an adulterated or 
10
counterfeit drug to an individual in the United 
11
States; or 
12
‘‘(2) dispenses, by means of the internet, a drug 
13
to an individual in the United States who the person 
14
knows or has reasonable cause to believe, does not 
15
possess a valid prescription for that drug, 
16
such person shall be imprisoned for not more than 10 
17
years or fined not more than $250,000.’’. 
18
(c) NO PREEMPTION.—Nothing in this Act, including 
19
the amendments made by this Act, shall be construed to 
20
preempt, alter, displace, abridge, or supplant any remedy 
21
available under any State or Federal law, including com-
22
mon law, that provides a remedy for civil relief. 
23
(d) REPORTS.— 
24
03:07 Mar 14, 2019
H1478
18 
•HR 1478 IH
(1) HHS.—Not later than 1 year after the date 
1
on which final regulations are promulgated to carry 
2
out section 804A of the Federal Food, Drug, and 
3
Cosmetic Act (21 U.S.C. 384), as added by this Act, 
4
and every 2 years thereafter, the Secretary of 
5
Health and Human Services, after consultation with 
6
appropriate Federal agencies, shall submit to Con-
7
gress and make public a report on the importation 
8
of insulin into the United States. 
9
(2) GAO REPORT.—Not later than 18 months 
10
after the date on which final regulations are promul-
11
gated to carry out section 804A of the Federal 
12
Food, Drug, and Cosmetic Act (21 U.S.C. 384), as 
13
added by this Act, the Comptroller General of the 
14
United States shall submit to Congress a report con-
15
taining an analysis of the implementation of the 
16
amendments made by this Act, including a review of 
17
drug safety and cost-savings and expenses, including 
18
cost-savings to consumers in the United States and 
19
trans-shipment and importation tracing processes, 
20
resulting from such implementation. 
21
Æ 
03:07 Mar 14, 2019
H1478
